Biomarker Analysis from the Compass Claudication Study - Rivaroxaban for Intermittent Claudication.

Area of Science:

• Cardiovascular Medicine
• Pharmacology
• Biomarker Research

Background:

• Peripheral artery disease (PAD) and intermittent claudication impact walking ability.
• Coagulation and inflammatory biomarkers may offer prognostic insights in PAD.
• Previous studies suggest rivaroxaban plus aspirin improves walking distance in PAD patients.

Purpose of the Study:

• To investigate the effect of rivaroxaban plus aspirin versus aspirin alone on coagulation and inflammatory biomarkers.
• To determine if these biomarkers can serve as prognostic indicators in intermittent claudication.
• To inform clinical decision-making in PAD management.

Main Methods:

• A prospective, randomized, multicenter biomarker substudy.
• Inclusion of 36 patients with PAD and intermittent claudication from two treatment arms (rivaroxaban + aspirin vs. aspirin alone).
• Measurement of plasma biomarkers including D-dimer, von Willebrand factor, thrombin generation potential, PAI-1, TAFI, and CRP at baseline and 24 weeks.

Main Results:

• No significant differences in assessed coagulation or inflammatory biomarkers were found between the rivaroxaban plus aspirin group and the aspirin alone group.
• Biomarker levels remained comparable between the treatment arms after 24 weeks of intervention.
• The addition of rivaroxaban to aspirin did not lead to detectable changes in these specific biomarkers.

Conclusions:

• Treatment with rivaroxaban plus aspirin did not significantly alter coagulation or inflammatory biomarkers compared to aspirin alone in patients with intermittent claudication.
• The study did not identify differences in these biomarkers that could explain the observed improvements in walking distance.
• Further research may be needed to identify other biomarkers or mechanisms involved in PAD treatment response.